Trial Profile

Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

18 Oct 2024 Results(n=59) exploring the potential of tumor in situ fluid circulating tumor DNA (TISF-ctDNA) dynamics in predicting treatment efficacy , published in the Journal of Cancer Research and Clinical Oncology
25 Sep 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2027.
25 Sep 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com